CA
NZ
UK
AU
IND
US
…
Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products. It also provides harvested cannabis, trim, cannabis oils, capsules, edibles, vaporizers, dried and fresh cannabis, cannabis plants, cannabis seeds, edible cannabis, cannabis extracts, flowers, vapes / inhalable extracts, edibles / pastilles, concentrates, and cannabis topicals; and patient counseling and outreach services. Its brand portfolio includes Aurora, Being, CanniMed, CraftPlant, Daily Special, Drift, Greybeard, IndiMed, MedReleaf, Pedanios, San Raf, Tasty's, Whistler, and WMMC. The company also engages in pharmacy activities. Aurora Cannabis Inc. was founded in 2013 and is headquartered in Edmonton, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Aurora Cannabis Inc is a Canada-based producer and distributor of medical and adult-use cannabis, operating cultivation and distribution across multiple jurisdictions. Long-term growth drivers include wider legalization, product diversification, international expansion and cost reductions from restructuring, which may support revenue and margin recovery. Investors may find the company attractive for its position in regulated markets and potential to improve profitability through scale and cost cuts.
Key investment risks include ongoing unprofitability, high leverage and liquidity uncertainty, regulatory and pricing pressure from oversupply and intense competition that could impede execution.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-06-30 |
| Income before tax | -56.52M | 20.38M | -59.60M | -295.42M | -1720.12M |
| Minority interest | 0.00M | - | - | 2.06M | 0.35M |
| Net income | -121.76M | 1.59M | -69.33M | -265.33M | -1717.62M |
| Selling general administrative | 106.57M | 110.19M | 104.94M | 68.22M | 126.97M |
| Selling and marketing expenses | 59.64M | 56.28M | 51.94M | 51.97M | 62.02M |
| Gross profit | 136.65M | 187.61M | 131.46M | -64.36M | 21.23M |
| Reconciled depreciation | 14.19M | 22.55M | 33.07M | 65.23M | 93.66M |
| Ebit | -54.72M | 28.80M | -12.60M | -254.32M | -236.75M |
| Ebitda | -50.90M | 51.35M | 20.47M | -210.74M | -143.09M |
| Depreciation and amortization | 3.81M | 22.55M | 33.07M | 43.57M | 93.66M |
| Operating income | -46.66M | 4.95M | -46.45M | -254.32M | -231.45M |
| Other operating expenses | 367.25M | 338.35M | 297.36M | 487.61M | 440.71M |
| Interest expense | 1.81M | 8.42M | 14.19M | 39.46M | 71.81M |
| Tax provision | 2.10M | 4.62M | -0.55M | -13.64M | -2.14M |
| Interest income | 5.85M | 11.51M | 12.81M | 9.88M | 4.51M |
| Net interest income | 4.04M | 3.08M | -1.37M | -51.52M | -67.31M |
| Income tax expense | 2.10M | 4.62M | -0.55M | -20.32M | -2.14M |
| Total revenue | 320.59M | 343.29M | 270.28M | 233.29M | 221.34M |
| Total operating expenses | 183.31M | 182.66M | 158.54M | 189.96M | 240.60M |
| Cost of revenue | 183.94M | 155.69M | 138.82M | 297.65M | 200.11M |
| Total other income expense net | -9.86M | 15.43M | -31.15M | -41.10M | -1433.44M |
| Net income from continuing ops | -58.62M | 15.76M | -59.05M | -1750.02M | -1717.98M |
| Net income applicable to common shares | - | - | - | - | -1717.62M |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-06-30 | 2023-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-06-30 | 2023-03-31 |
| Total assets | 602.64M | 847.77M | 838.67M | 926.32M | 926.32M |
| Intangible assets | 31.52M | 44.90M | 40.85M | 61.40M | 61.40M |
| Other current assets | 13.14M | 10.82M | 9.40M | 8.92M | 8.92M |
| Total liab | 89.49M | 242.67M | 236.80M | 409.19M | 409.19M |
| Total stockholder equity | 513.15M | 563.91M | 559.77M | 486.08M | 486.08M |
| Other current liab | 50.75M | 44.84M | 21.02M | 71.07M | 48.97M |
| Common stock | 7025.33M | 6950.98M | 6971.42M | 6841.23M | 6841.23M |
| Capital stock | 7007.23M | 6991.15M | 6971.42M | - | - |
| Retained earnings | -6458.56M | -6331.15M | -6367.94M | -6296.83M | -6296.83M |
| Good will | 26.72M | 43.62M | 43.18M | 18.71M | 18.71M |
| Cash | 112.77M | 184.26M | 113.44M | 300.84M | 300.84M |
| Total current liabilities | 67.10M | 110.23M | 124.62M | 242.31M | 242.31M |
| Current deferred revenue | 1.27M | 1.07M | 1.69M | 1.74M | 1.74M |
| Net debt | -88.85M | -80.28M | -8.65M | -73.32M | -73.32M |
| Short term debt | 5.74M | 26.74M | 57.22M | 147.56M | 147.56M |
| Short long term debt | - | 21.51M | 52.36M | - | - |
| Short long term debt total | 23.92M | 103.98M | 104.79M | 227.52M | 227.52M |
| Other stockholder equity | 160.52M | - | - | -0.00M | -0.00M |
| Total current assets | 398.48M | 475.58M | 426.61M | 479.93M | 479.93M |
| Long term investments | 12.11M | - | - | - | - |
| Short term investments | 52.35M | 0.55M | 4.04M | - | - |
| Net receivables | 44.69M | 42.23M | 45.41M | 41.34M | 41.34M |
| Long term debt | - | 40.19M | 4.90M | - | - |
| Inventory | 175.53M | 237.72M | 186.38M | 128.82M | 128.82M |
| Accounts payable | 9.33M | 27.46M | 20.32M | 21.94M | 21.94M |
| Accumulated other comprehensive income | -214.15M | -55.91M | -43.71M | -58.32M | -58.32M |
| Non currrent assets other | 3.63M | 7.68M | 12.03M | 14.06M | 14.06M |
| Non current assets total | 204.16M | 372.19M | 412.07M | 446.39M | 446.39M |
| Capital lease obligations | 23.86M | 42.88M | 47.53M | - | - |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-06-30 |
| Investments | -52.21M | -14.33M | -5.49M | -54.67M | -36.60M |
| Change to liabilities | - | - | - | - | 3.31M |
| Total cashflows from investing activities | -72.61M | -14.33M | - | - | -36.60M |
| Net borrowings | -5.02M | -0.81M | - | - | -170.83M |
| Total cash from financing activities | 9.76M | -0.12M | -47.92M | -56.48M | 147.78M |
| Change to operating activities | - | - | - | - | 6.47M |
| Net income | -58.62M | 15.76M | -59.05M | -265.33M | -1717.98M |
| Change in cash | -73.23M | 1.83M | -121.50M | -140.01M | 16.35M |
| Begin period cash flow | 137.92M | 136.09M | 234.94M | 440.85M | 421.46M |
| End period cash flow | 64.69M | 137.92M | 113.44M | 300.84M | 437.81M |
| Total cash from operating activities | -13.51M | 16.00M | -68.51M | -115.82M | -109.84M |
| Issuance of capital stock | 10.91M | 0.00M | 37.93M | 417.75M | 350.19M |
| Depreciation | 14.19M | 22.55M | 33.07M | 43.57M | 93.66M |
| Other cashflows from investing activities | 2.15M | -0.96M | - | - | -0.18M |
| Change to inventory | 7.44M | -15.05M | 3.62M | 49.03M | 21.07M |
| Change to account receivables | -8.15M | 5.24M | -4.33M | 5.53M | 18.76M |
| Other cashflows from financing activities | 3.29M | -0.13M | -5.49M | -95.21M | -31.58M |
| Change to netincome | - | - | - | - | 1464.18M |
| Capital expenditures | 22.55M | 18.86M | 16.96M | 12.13M | 32.21M |
| Change in working capital | -9.21M | 10.21M | -15.63M | -25.12M | 49.95M |
| Stock based compensation | 7.29M | 11.52M | 12.72M | 16.89M | 13.76M |
| Other non cash items | 32.78M | -40.85M | -70.84M | 190.11M | 1452.97M |
| Free cash flow | -36.06M | -2.85M | -85.46M | -127.95M | -142.05M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ACB Aurora Cannabis Inc |
-0.07 1.69% |
4.08 | - | 109.89 | 0.77 | 0.63 | 0.82 | 15.32 |
| MKKGY Merck KGaA ADR |
0.37 1.15% |
32.62 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
158.72 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.12 0.59% |
20.15 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
-3.18 7.73% |
37.97 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products. It also provides harvested cannabis, trim, cannabis oils, capsules, edibles, vaporizers, dried and fresh cannabis, cannabis plants, cannabis seeds, edible cannabis, cannabis extracts, flowers, vapes / inhalable extracts, edibles / pastilles, concentrates, and cannabis topicals; and patient counseling and outreach services. Its brand portfolio includes Aurora, Being, CanniMed, CraftPlant, Daily Special, Drift, Greybeard, IndiMed, MedReleaf, Pedanios, San Raf, Tasty's, Whistler, and WMMC. The company also engages in pharmacy activities. Aurora Cannabis Inc. was founded in 2013 and is headquartered in Edmonton, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Miguel Martin | CEO & Director | 1972 |
| Mr. Glen Ibbott | Chief Financial Officer | NA |
| Mr. Alex Miller | Exec. VP of Operations & Supply Chain | NA |
| Ms. Lori Schick | Exec. VP of HR | NA |
| Mr. Andre Jerome | Exec. VP of Global Bus. Devel. | NA |
| Ananth Krishnan | VP of Capital Markets & Investor Relations | NA |
| Mr. Nathalie Clark | Exec. VP, Gen. Counsel & Corp. Sec. | NA |
| Michelle Lefler | VP of Communications & PR | NA |
| Mr. Carey Squires | Exec. VP of Corp. Devel. & Strategy | NA |
| Mr. John Barnet | Chief Cultivator | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.02%
Communication Services
-0.63%
Consumer Cyclical
-0.11%
Consumer Defensive
-0.45%
Energy
+0.39%
Financial Services
-0.10%
Financials
-0.81%
Healthcare
+1.03%
Industrials
+0.32%
Real Estate
-0.31%
Technology
+0.59%
Utilities
-0.18%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...